229 related articles for article (PubMed ID: 15994369)
41. VPAC and PAC receptors: From ligands to function.
Dickson L; Finlayson K
Pharmacol Ther; 2009 Mar; 121(3):294-316. PubMed ID: 19109992
[TBL] [Abstract][Full Text] [Related]
42. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability.
Dangoor D; Biondi B; Gobbo M; Vachutinski Y; Fridkin M; Gozes I; Rocchi R
J Pept Sci; 2008 Mar; 14(3):321-8. PubMed ID: 17924396
[TBL] [Abstract][Full Text] [Related]
43. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.
Ceraudo E; Tan YV; Couvineau A; Lacapere JJ; Laburthe M
Ann N Y Acad Sci; 2006 Jul; 1070():180-4. PubMed ID: 16888162
[TBL] [Abstract][Full Text] [Related]
44. A complete substitutional analysis of VIP for better tumor imaging properties.
Bhargava S; Licha K; Knaute T; Ebert B; Becker A; Grötzinger C; Hessenius C; Wiedenmann B; Schneider-Mergener J; Volkmer-Engert R
J Mol Recognit; 2002; 15(3):145-53. PubMed ID: 12203840
[TBL] [Abstract][Full Text] [Related]
45. Cyclic AMP formation in C6 glioma cells: effect of PACAP and VIP in early and late passages.
Sokolowska P; Nowak JZ
Ann N Y Acad Sci; 2006 Jul; 1070():566-9. PubMed ID: 16888226
[TBL] [Abstract][Full Text] [Related]
46. All D-VIP mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo.
Rubinstein I; Ashok B; Tsueshita T; Onyüksel H
Peptides; 2005 Mar; 26(3):509-15. PubMed ID: 15652658
[TBL] [Abstract][Full Text] [Related]
47. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma.
Bolin DR; Michalewsky J; Wasserman MA; O'Donnell M
Biopolymers; 1995; 37(2):57-66. PubMed ID: 7893947
[TBL] [Abstract][Full Text] [Related]
48. Tryptophan 67 in the human VPAC(1) receptor: crucial role for VIP binding.
Nicole P; Maoret JJ; Couvineau A; Momany FA; Laburthe M
Biochem Biophys Res Commun; 2000 Sep; 276(2):654-9. PubMed ID: 11027527
[TBL] [Abstract][Full Text] [Related]
49. Endogenous ligands of PACAP/VIP receptors in the autocrine-paracrine regulation of the adrenal gland.
Conconi MT; Spinazzi R; Nussdorfer GG
Int Rev Cytol; 2006; 249():1-51. PubMed ID: 16697281
[TBL] [Abstract][Full Text] [Related]
50. Identification of key residues that cause differential gallbladder response to PACAP and VIP in the guinea pig.
Wei M; Fujiki K; Ando E; Zhang S; Ozaki T; Ishiguro H; Kondo T; Nokihara K; Wray V; Naruse S
Am J Physiol Gastrointest Liver Physiol; 2007 Jan; 292(1):G76-83. PubMed ID: 16901992
[TBL] [Abstract][Full Text] [Related]
51. Role of VIP and PACAP in islet function.
Winzell MS; Ahrén B
Peptides; 2007 Sep; 28(9):1805-13. PubMed ID: 17559974
[TBL] [Abstract][Full Text] [Related]
52. Generation of PEGylated VPAC1-selective antagonists that inhibit proliferation of a lung cancer cell line.
Pan CQ; Hamren S; Roczniak S; Tom I; DeRome M
Peptides; 2008 Mar; 29(3):479-86. PubMed ID: 17942192
[TBL] [Abstract][Full Text] [Related]
53. Characterization of the new photoaffinity probe (Bz2-K24)-VIP.
Tan YV; Couvineau A; Lacapere JJ; Laburthe M
Ann N Y Acad Sci; 2006 Jul; 1070():575-80. PubMed ID: 16888228
[TBL] [Abstract][Full Text] [Related]
54. PACAP, VIP and their receptors in the metazoa: insights about the origin and evolution of the ligand-receptor pair.
Cardoso JC; Vieira FA; Gomes AS; Power DM
Peptides; 2007 Sep; 28(9):1902-19. PubMed ID: 17826180
[TBL] [Abstract][Full Text] [Related]
55. VPAC1 receptor binding site: contribution of photoaffinity labeling approach.
Couvineau A; Ceraudo E; Tan YV; Laburthe M
Neuropeptides; 2010 Apr; 44(2):127-32. PubMed ID: 20031208
[TBL] [Abstract][Full Text] [Related]
56. Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation.
Langer I; Robberecht P
Cell Signal; 2005 Jan; 17(1):17-24. PubMed ID: 15451021
[TBL] [Abstract][Full Text] [Related]
57. The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery.
Boni LJ; Ploug KB; Olesen J; Jansen-Olesen I; Gupta S
Cephalalgia; 2009 Aug; 29(8):837-47. PubMed ID: 19220306
[TBL] [Abstract][Full Text] [Related]
58. PACAP, VIP, and PHI: effects on AC-, PLC-, and PLD-driven signaling systems in the primary glial cell cultures.
Dejda A; Jozwiak-Bebenista M; Nowak JZ
Ann N Y Acad Sci; 2006 Jul; 1070():220-5. PubMed ID: 16888170
[TBL] [Abstract][Full Text] [Related]
59. Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.
Valdehita A; Carmena MJ; Collado B; Prieto JC; Bajo AM
Regul Pept; 2007 Dec; 144(1-3):101-8. PubMed ID: 17683807
[TBL] [Abstract][Full Text] [Related]
60. The effects of vasoactive intestinal peptide on human natural killer cell function.
Rola-Pleszczynski M; Bolduc D; St-Pierre S
J Immunol; 1985 Oct; 135(4):2569-73. PubMed ID: 2993412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
